Aprea Therapeutics, Inc. APRE
We take great care to ensure that the data presented and summarized in this overview for Aprea Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in APRE
Top Purchases
Top Sells
About APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Insider Transactions at APRE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 23
2024
|
Oren Gilad President/CEO |
BUY
Open market or private purchase
|
Direct |
500
+0.15%
|
$1,500
$3.92 P/Share
|
|
Oct 18
2024
|
Marc Duey Director |
SELL
Open market or private sale
|
Direct |
6,462
-2.69%
|
$25,848
$4.58 P/Share
|
|
Oct 16
2024
|
Marc Duey Director |
BUY
Open market or private purchase
|
Direct |
30,000
+11.11%
|
$120,000
$4.39 P/Share
|
|
Oct 15
2024
|
Oren Gilad President/CEO |
BUY
Open market or private purchase
|
Direct |
250
+0.08%
|
$500
$2.9 P/Share
|
|
Oct 14
2024
|
Marc Duey Director |
BUY
Open market or private purchase
|
Direct |
190
+0.09%
|
$380
$2.58 P/Share
|
|
Oct 14
2024
|
Oren Gilad President/CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.3%
|
$2,000
$2.59 P/Share
|
|
Oct 11
2024
|
John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr |
BUY
Open market or private purchase
|
Direct |
50
+0.26%
|
$100
$2.46 P/Share
|
|
Oct 11
2024
|
Bernd R. Seizinger Director |
BUY
Open market or private purchase
|
Direct |
10,000
+18.27%
|
$20,000
$2.68 P/Share
|
|
Oct 10
2024
|
John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr |
BUY
Open market or private purchase
|
Direct |
450
+2.28%
|
$900
$2.61 P/Share
|
|
Oct 10
2024
|
Oren Gilad President/CEO |
BUY
Open market or private purchase
|
Direct |
150
+0.05%
|
$300
$2.54 P/Share
|
|
Jun 20
2024
|
Bernd R. Seizinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,045
+2.92%
|
-
|
|
Jun 20
2024
|
Marc Duey Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,045
+0.5%
|
-
|
|
Jun 20
2024
|
Michael Grissinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,045
+36.17%
|
-
|
|
Jun 20
2024
|
John B Henneman Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,045
+10.22%
|
-
|
|
Jun 20
2024
|
Richard Peters Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,045
+33.5%
|
-
|
|
Jun 20
2024
|
Rifat Pamukcu Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,045
+19.19%
|
-
|
|
May 01
2024
|
Nadeem Q. Mirza Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,730
+50.0%
|
-
|
|
Mar 28
2024
|
John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
3,365
+15.14%
|
-
|
|
Mar 28
2024
|
Oren Gilad President/CEO |
BUY
Grant, award, or other acquisition
|
Direct |
6,725
+1.99%
|
-
|
|
Mar 13
2024
|
John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr |
BUY
Open market or private purchase
|
Direct |
1,010
+6.12%
|
$7,070
$7.29 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 23.1K shares |
|---|---|
| Open market or private purchase | 59.3K shares |
| Open market or private sale | 6.46K shares |
|---|